BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  AlloVir Reports Second Quarter 2022 Financial Results

  AlloVir, Inc. (Nasdaq: ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the second quarter ended June 30, 2022.

  August 4, 2022

   · 

  11 min read
• Business

  BeiGene Reports Second Quarter 2022 Financial Results

  BeiGene, Ltd. today reported financial results for the second quarter of 2022, recent business highlights, and anticipated upcoming milestones.

  August 4, 2022

   · 

  21 min read
• Business

  ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*

  ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended June 30, 2022.

  August 4, 2022

   · 

  17 min read
• Biotech Bay

  CareDx Unveils New Patient-Centered Medication Management Features on AlloCare Mobile Health App

  CareDx, Inc. today announced that its AlloCare® mobile health app features expanded medication adherence and patient-provider communication capabilities resulting from the successful integration of MedActionPlan®, an acquisition made last year.

  August 4, 2022

   · 

  5 min read
• Deals

  invoX Pharma Extends Tender Offer to Acquire F-star Therapeutics, Inc.

  invoX Pharma Limited and F-star Therapeutics, Inc. today announced that invoX has extended the expiration of its previously announced tender offer for all of the issued and outstanding shares of F-star common stock for a price of $7.12 per share.

  August 4, 2022

   · 

  10 min read
• Business

  Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update.

  August 4, 2022

   · 

  11 min read
• Business

  Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

  Selecta Biosciences, Inc. today reported financial results for the second quarter ended June 30, 2022 and provided a business update.

  August 4, 2022

   · 

  15 min read
• Business

  Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

  Intellia Therapeutics, Inc. today reported operational highlights and financial results for the second quarter ended June 30, 2022.

  August 4, 2022

   · 

  17 min read
• Biotech Bay

  Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

  Vera Therapeutics, Inc. today announced that the Company’s management team will present at the 13th Annual Wedbush PacGrow Healthcare Conference, which is taking place virtually August 9-10, 2022.

  August 4, 2022

   · 

  1 min read
• Business

  Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022 and will provide a business update.

  August 4, 2022

   · 

  1 min read